Figures from the publication by Davis and collaborators. DUF1220 dosage is distributed in patients with autism spectrum disorders (ASD) in an almost Gaussian fashion, which is not much different from what is expected in the general population. However, there is a linear correlation between DUF1220 dosage and various ASD-related features including measures for social deficits, communicative impairments, and repetitive behaviors (figure adapted from the publication by Davis and collaborators under a Creative Commons License).